Michel Ronc

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Part of TotalEnergies SE, Elf Technologies, Inc. is an American company.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.

Demeter Partners SA (Demeter Partners) is a French private equity firm which was founded in 2005 by Sophie Paturle-Guesnerot and Stéphane Villecroze and is majority-owned by the management team. Headquartered in Paris with an additional office in Madrid, Demeter Partners has partnerships with English, German and Spanish funds which are involved in their sectors and are also members of international networks of investors specialized in 'clean technologies'. The firm manages the Demeter Fund, sponsored by the Caisse des Dépôts (CDC Entreprises) and the Institut Français du Pétrole (French Petroleum Institute) for institutional investors including life insurance companies, health insurance companies, pension funds and sophisticated private investors.